Introduction to Gentamicin

Gentamicin, the most commonly used aminoglycoside antibiotic, is highly effective against moderate-to-severe bacterial infections caused by sensitive agents, particularly gram-negative bacteria. Its mechanism of action involves binding to bacterial ribosomes and disrupting protein synthesis. This inhibition of protein production ultimately leads to the death of the bacteria. Gentamicin has been widely used in the medical field due to its effectiveness against broad-spectrum bacteria.

Browse all Gentamicin products

Pharmacology of Gentamicin

Gentamicin is a bactericidal antibiotic that exerts its pharmacological effects by binding to the 30S subunit of the bacterial ribosome, specifically at helix 44 of the 16S rRNA. This binding disrupts the ribosome's ability to properly discriminate between correct and incorrect transfer RNA (tRNA) and messenger RNA (mRNA) interactions during protein synthesis. Normally, if an incorrect tRNA pairs with an mRNA codon, adenosines 1492 and 1493 retract, signaling the ribosome to reject the aminoacylated tRNA complex. However, when gentamicin binds at helix 44, it prevents the retraction of these adenosines, leading to the acceptance of incorrect aminoacyl-tRNAs. As a result, the ribosome synthesizes proteins with incorrect amino acids incorporated throughout the chain, typically occurring at a rate of approximately one error in every 500 amino acids. These non-functional, mistranslated proteins misfold and aggregate, ultimately leading to bacterial cell death.

In addition to its primary binding site, gentamicin has a secondary binding site at helix 69 of the 23S rRNA. This binding site interacts with helix 44 and proteins involved in recognizing stop codons. Gentamicin's presence at this secondary site prevents the ribosome from interacting with ribosome recycling factors, leading to the formation of inactive ribosome complexes even after translation is complete. This results in a pool of non-functional ribosomes within the bacterial cell that cannot re-initiate translation and synthesize new proteins.

Gentamicin is primarily administered parenterally (via intravenous or intramuscular routes) due to its poor oral bioavailability. It has limited absorption from the gastrointestinal tract. Gentamicin exhibits a concentration-dependent pharmacokinetic profile, with higher peak concentrations associated with improved bactericidal activity. It has a relatively large volume of distribution, allowing it to distribute widely into various tissues and body fluids. Gentamicin is eliminated primarily by renal excretion, and its dosage needs to be adjusted based on renal function to avoid toxicity.

• Residual gentamicin in vaccine
  Antibiotics including neomycin, polymyxin B, streptomycin, and gentamicin are used to prevent bacterial contamination during vaccine production. Most antibiotics are removed during the vaccine purification process, but trace amounts remain in some vaccines. Because antibiotics can cause severe allergic reactions in children (such as hives, swelling in the back of the throat, and low blood pressure), it is necessary to test the antibiotics in vaccines to check that they meet the levels of antibiotics in vaccines licensed for use to ensure safety.
• Residual gentamicin in animal-derived food products
  The use of gentamicin in veterinary medicine for the treatment of bacterial infections in livestock can lead to residue accumulation. This has raised concerns regarding the potential health risks associated with the consumption of such products.
  Regulatory authorities have established maximum residue limits (MRLs) for gentamicin in food products to ensure consumer safety. These limits are based on extensive research and toxicological studies to determine the acceptable levels of residue that can be present without posing significant health risks.

Gentamicin-Related Antibodies

Gentamicin-Related Antigens

Gentamicin-Related ELISA Kits